Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’
Jun 14 2024
•
By
Sue Sutter
FDA quickly changed course on its COVID vaccine formulation recommendations for 2024-2025. • Source: Shutterstock
More from Vaccines
More from Pink Sheet